SEC Comment Letter for Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Nov 21, 2016
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Nov. 21, 2016 · CIK: 0001503802 · Accession: 0000000000-16-101786
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214489
Letter
Mail Stop 4546 November 18, 2016 Michael G. Kauffman, M.D., Ph.D. Chief Executive Officer Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459
Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 Filed November 8, 2016 File No. 333-214489
Dear Dr. Kauffman :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Scot Foley at (202) 551 -3383 or Mary Beth Breslin at (202) 551 -3625 with any questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546
November 18, 2016
Michael G. Kauffman, M.D., Ph.D.
Chief Executive Officer
Karyopharm Therapeutics Inc.
85 Wells Avenue, 2nd Floor
Newton, MA 02459
Re: Karyopharm Therapeutics Inc.
Registration Statement on Form S-3
Filed November 8, 2016
File No. 333-214489
Dear Dr. Kauffman :
This is to advise you that we have not reviewed and will not review your registration
statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Scot Foley at (202) 551 -3383 or Mary Beth Breslin at (202) 551 -3625 with
any questions.
Sincerely,
/s/ Mary Beth Breslin for
Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance
cc: Steven D. Singer, Esq.